Source: FDA, National Drug Code (US) Revision Year: 2025
RHAPSIDO (remibrutinib) is a kinase inhibitor.
Its empirical formula (remibrutinib) is C27H27F2N5O3. The chemical name for remibrutinib is N-(3-{6-Amino-5-[2-(N-methylprop-2-enamido)ethoxy]pyrimidin-4-yl}-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide. Its molecular weight is approximately 507.54 g/mol. The chemical structure of remibrutinib is:
Remibrutinib is white to pale yellow powder, and it is practically insoluble in water.
RHAPSIDO is supplied as film-coated tablets for oral administration, with each film-coated tablet containing 25 mg of remibrutinib. The tablet core inactive ingredients are copovidone, croscarmellose sodium, mannitol, microcrystalline cellulose, sodium lauryl sulfate, and sodium stearyl fumarate. The tablet coating inactive ingredients are polyethylene glycol 4000, polyvinyl alcohol, red iron oxide (E172), talc, titanium dioxide (E171), and yellow iron oxide (E172).
| Dosage Forms and Strengths |
|---|
|
Tablets: 25 mg, light yellow, round, curved, unscored, film-coated tablet, debossed with "LV" on one side and Novartis logo on the other side. The tablet diameter is 7 mm. |
| How Supplied | ||||||||
|---|---|---|---|---|---|---|---|---|
|
RHAPSIDO tablets are supplied as described in Table 4: Table 4. RHAPSIDO Tablets and Package Configuration:
Distributed by: Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, New Jersey 07936 |
| Drug | Countries | |
|---|---|---|
| RHAPSIDO | United States |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.